In Brief: Cambridge Biotech
This article was originally published in The Gray Sheet
Executive SummaryCambridge Biotech: U.S. Bankruptcy Court upholds the company's license to HIV-2 tests from Pasteur Sanofi, which had been challenged by Institut Pasteur and Genetic Systems in a patent infringement suit filed in March. However, the court enjoined Cambridge Biotech from sale of its Western Blot HIV-1 test, ruling that it infringed an Institut Pasteur patent. Cambridge Biotech, which in July 1994 filed for bankruptcy under Chapter 11 of the U.S. Bankruptcy Code, says that the court's decisions will allow it to "move forward" with its reorganization...
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.